[1] |
XIE Rui, GENG Zihan, BAO Lei, ZHAO Ronghua, LI Shuran, SUN Qiyue, WANG Xinwei, ZHANG Jingsheng, CUI Xiaolan, GUO Shanshan, SUN Jing.
Research Progress in Pharmacological Actions, Mechanisms, Structural Modifications and Targeted Formulations of Ribavirin
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 950-955.
|
[2] |
LIU Ming, ZHENG Li, ZHANG Weina, SUN Xuelin, TIAN Jinhui, ZHAO Yan.
Research Progress in Biological Activity and Mechanisms of Pachymic Acid
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 826-830.
|
[3] |
YE Ling, LIU Xiaoying, DANG Xuefei, LI Xuelian, LI Gang.
Research Progress in Drugs for Brain Metastases from Advanced Breast Cancer
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 714-720.
|
[4] |
BAI Xue, CHEN Yafei, TANG Tian, LIU Zhejun, WANG Guoyu, TAN Tianyang.
Progress in Clinical and Pharmacological Research of Angong Niuhuang Pills
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(3): 349-356.
|
[5] |
LI Wenpeng, LIU Mingyu, CAO Ying, ZHOU Huziwei, WANG Shengfeng.
Supervision status and research progress of global abuse of opioids
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(5): 513-518.
|
[6] |
ZHOU Yue, LIU Shuo, SONG Haibo.
Roles of licensed pharmacists in drug classification management
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(4): 428-434.
|
[7] |
NING Xiao, GAO Guanghui, JIN Shaoming, LIU Tongtong, PEI Yusheng, CAO Jin.
Determination of erythromycin ointment content based on on-line column switching and liquid chromatography
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 152-155.
|
[8] |
LIU Sujie, YAN Jiahe, RUAN Jiaxin, WANG Chen, WANG Xiaofan, LIU Shumin, BAI Xue.
Research Progress in Regulation of Wnt/β-Catenin Signaling Pathway by TCM in the Treatment of Ischemic Stroke
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(12): 1388-1392.
|
[9] |
BAI Xue, CHEN Yafei, TANG Tian, LIU Zhejun, TAN Tianyang, LIU Zhenquan.
Research Progress on the Potential Therapeutic Effect of Bushen Shengjing Prescription on Oligoasthenozoospermia
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(11): 1243-1249.
|
[10] |
CONG Duanduan, XUE Wei, LIU Yue, QI Wenyuan, LIU Xiaohui, WANG Juan, LI Kexin, HU Xin.
Management of Safety Information in Prescription Drug Labeling in China, Japan and the United States
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(3): 245-249.
|
[11] |
WANG Yanchun, WANG Jianqiang.
Research Progress in Clinical Application of Shuganning Injection
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(8): 543-547.
|
[12] |
LI Sizheng, HU Guang, HE Jingcheng, HU Yuchi, LI Zhiyong, JIN Hongtao.
The Role of Renin-angiotensin System in COVID-19 and Drug Intervention
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(5): 267-271.
|
[13] |
TIAN Chunhua, XIA Dongsheng.
"Double Classification" Management of Prescription Drugs and Non-prescription Drugs in China based on British System
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(12): 883-884.
|
[14] |
ZHU Lan, Shao Bo, XIA Dongsheng.
Selection and Switch-to-OTC of Chinese Patent Medicines in China
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(11): 785-789.
|
[15] |
QIU Caixia, YANG Cuiping, JIN Hongtao.
Research Progress in Mechanisms of Drug-induced Kidney Injury
[J]. Chinese Journal of Pharmacovigilance, 2019, 16(11): 688-694.
|